Transmolecular Imaging of Recurrent Prostate Carcinoma With Exploration of Genomic Markers Differences Between Local and Distant Recurrence

Trial Profile

Transmolecular Imaging of Recurrent Prostate Carcinoma With Exploration of Genomic Markers Differences Between Local and Distant Recurrence

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 02 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 02 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 16 May 2017 Results comparing Fluciclovine (18F) Pet-Ct and Mri for detection of recurrent prostate cancer, presented at the 112th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top